Fetal Hyperthyroidism Secondary to Maternal Basedow–Graves' Disease

Julio Soto; Bunio Weissglas; Gustav von Plessing-Pierry; Maria Paz del Solar; Carolina Peña-Villa; Ximena Flores; Monica Arancibia; Laura Campos

doi:10.1055/a-2317-9431

American Journal of Perinatology Reports, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · AJP Rep 2024; 14(02): e176-e183
DOI: 10.1055/a-2317-9431

Case Report

Fetal Hyperthyroidism Secondary to Maternal Basedow–Graves' Disease

Julio Soto

¹Department of Pediatrics, School of Medicine, Universidad de Concepcion, Concepcion, Chile

²Division of Pediatric Endocrinology, Pediatrics Service, Hospital Las Higueras, Talcahuano, Chile

,

Bunio Weissglas

³Department of Internal Medicine, School of Medicine, Universidad de Concepcion, Concepcion, Chile

,

Gustav von Plessing-Pierry

³Department of Internal Medicine, School of Medicine, Universidad de Concepcion, Concepcion, Chile

,

Maria Paz del Solar

⁴Department of Clinical and Preclinical Sciences, School of Medicine, Universidad Catolica de la Santisima Concepcion, Concepcion, Chile

,

Carolina Peña-Villa

³Department of Internal Medicine, School of Medicine, Universidad de Concepcion, Concepcion, Chile

⁵Division of Endocrinology, Internal Medicine Service, Hospital Las Higueras, Talcahuano, Chile

,

Ximena Flores

⁶Division of Obstetric and Gynecologic Ultrasound, Obstetrics and Gynecology Service, Hospital Las Higueras, Talcahuano, Chile

⁷Department of Obstetrics and Ginecology, School of Medicine, Universidad de Concepcion, Concepcion, Chile

,

Monica Arancibia

²Division of Pediatric Endocrinology, Pediatrics Service, Hospital Las Higueras, Talcahuano, Chile

,

Laura Campos

²Division of Pediatric Endocrinology, Pediatrics Service, Hospital Las Higueras, Talcahuano, Chile

› Institutsangaben

Abstract

Fetal hyperthyroidism is a rare prenatal disease and can be life-threatening. The diagnosis is based on ultrasound in mothers with a history of Basedow–Graves' disease and elevation of thyrotropin receptor antibodies (TRAbs) levels. The treatment consists of antithyroid drugs. We present a mother with Basedow–Graves' disease, treated with radioactive iodine 16 years ago. She had an unplanned pregnancy at the age of 29 years, and an elevation of TRAbs (21 U/L) was found at the sixth week of pregnancy. At 22 weeks of gestation, fetal ultrasound displayed tachycardia, goiter, exophthalmos, and suspicion of craniosynostosis, hence methimazole was started. Concomitantly, suppressed maternal thyroid-stimulating hormone (TSH) was found. Her daughter was born at 33 + 6 weeks showing clinical and laboratory findings of hyperthyroidism. Consequently, treatment with methimazole was prescribed. Normal thyroid function was documented in the mother after giving birth. Clear explanation has not been found for the alteration of maternal TSH during pregnancy.

Keywords

fetal hyperthyroidism - Graves' disease - hyperthyroidism - fetal

Volltext

Referenzen

References
1 Eng L, Lam L. Thyroid function during the fetal and neonatal periods. Neoreviews 2020; 21 (01) e30-e36
2 Polak M, Legac I, Vuillard E, Guibourdenche J, Castanet M, Luton D. Congenital hyperthyroidism: the fetus as a patient. Horm Res 2006; 65 (05) 235-242
3 Léger J, Carel JC. Diagnosis and management of hyperthyroidism from prenatal life to adolescence. Best Pract Res Clin Endocrinol Metab 2018; 32 (04) 373-386
4 Léger J. Management of fetal and neonatal Graves' disease. Horm Res Paediatr 2017; 87 (01) 1-6
5 Luton D, Le Gac I, Vuillard E. et al. Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 2005; 90 (11) 6093-6098
6 León MC. Hipertiroidismo en el embarazo. Recién nacido hijo de madre con Enfermedad de Graves Hyperthyroidism in pregnancy. Newborn of mother with Graves disease. Rev Española Endocrinol Pediatr 2013; 5 (02) 35-40
7 Kurtoğlu S, Özdemir A. Fetal neonatal hyperthyroidism: diagnostic and therapeutic approachment. Turk Pediatri Ars 2017; 52 (01) 1-9
8 Spoke C, Martin C. Maternal Graves disease and abnormal CYP2D6 genotype with fetal hyperthyroidism. AACE Clin Case Rep 2020; 6 (04) e161-e164
9 Alexander EK, Pearce EN, Brent GA. et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017; 27 (03) 315-389
10 Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158 (01) 69-75
11 Srisupundit K, Sirichotiyakul S, Tongprasert F, Luewan S, Tongsong T. Fetal therapy in fetal thyrotoxicosis: a case report. Fetal Diagn Ther 2008; 23 (02) 114-116
12 Lembet A, Eroglu D, Kinik ST, Gurakan B, Kuscu E. Non-invasive management of fetal goiter during maternal treatment of hyperthyroidism in Grave's disease. Fetal Diagn Ther 2005; 20 (04) 254-257
13 Luton D, Fried D, Sibony O. et al Assessment of fetal thyroid function by colored Doppler echography. Fetal Diagn Ther 1997; 12 (01) 24-27
14 Donnelly MA, Wood C, Casey B, Hobbins J, Barbour LA. Early severe fetal Graves disease in a mother after thyroid ablation and thyroidectomy. Obstet Gynecol 2015; 125 (05) 1059-1062
15 Kazakou P, Theodora M, Kanaka-Gantenbein C. et al Fetal hyperthyroidism associated with maternal thyroid autoantibodies: A case report. Case Rep Womens Health 2018; 20: e00081
16 Wallace C, Couch R, Ginsberg J. Fetal thyrotoxicosis: a case report and recommendations for prediction, diagnosis, and treatment. Thyroid 1995; 5 (02) 125-128
17 Wenstrom KD, Weiner CP, Williamson RA, Grant SS. Prenatal diagnosis of fetal hyperthyroidism using funipuncture. Obstet Gynecol 1990; 76 (3 Pt 2): 513-517
18 Hadi HA, Strickland D. Prenatal diagnosis and management of fetal goiter caused by maternal Grave's disease. Am J Perinatol 1995; 12 (04) 240-242
19 Porreco RP, Bloch CA. Fetal blood sampling in the management of intrauterine thyrotoxicosis. Obstet Gynecol 1990; 76 (3 Pt 2): 509-512
20 Vali A, Wiles P, Thomas NB, Ludlam A. Relapse of maternal thyrotoxicosis presenting as a second-trimester fetal goiter. Ultrasound Obstet Gynecol 1993; 3 (06) 429-431
21 Belfar HL, Foley Jr TP, Hill LM, Kislak S. Sonographic findings in maternal hyperthyroidism. Fetal hyperthyroidism/fetal goiter. J Ultrasound Med 1991; 10 (05) 281-284
22 Pekonen F, Teramo K, Mäkinen T, Ikonen E, Osterlund K, Lamberg BA. Prenatal diagnosis and treatment of fetal thyrotoxicosis. Am J Obstet Gynecol 1984; 150 (07) 893-894
23 Hatjis CG. Diagnosis and successful treatment of fetal goitrous hyperthyroidism caused by maternal Graves disease. Obstet Gynecol 1993; 81 (5( Pt 2)): 837-839
24 Heckel S, Favre R, Schlienger JL, Soskin P. Diagnosis and successful in utero treatment of a fetal goitrous hyperthyroidism caused by maternal Graves' disease. A case report. Fetal Diagn Ther 1997; 12 (01) 54-58 .11-18
25 Tongsong T, Wanapirak C, Kunavikatikul C, Sirirchotiyakul S, Piyamongkol W, Chanprapaph P. Fetal loss rate associated with cordocentesis at midgestation. Am J Obstet Gynecol 2001; 184 (04) 719-723
26 Somers EC. Pregnancy and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol 2020; 64: 3-10
27 Kobaly K, Mandel SJ. Hyperthyroidism and pregnancy. Endocrinol Metab Clin North Am 2019; 48 (03) 533-545
28 Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013; 1 (03) 238-249
29 James SR, Franklyn JA, Kilby MD. Placental transport of thyroid hormone. Best Pract Res Clin Endocrinol Metab 2007; 21 (02) 253-264
30 Blackburn S. Maternal-fetal thyroid interactions. J Perinat Neonatal Nurs 2009; 23 (04) 312-313
31 Banovac K, Ryan EA, O'Sullivan MJ. Triiodothyronine (T3) nuclear binding sites in human placenta and decidua. Placenta 1986; 7 (06) 543-549
32 Schmidt RL, LoPresti JS, McDermott MT, Zick SM, Straseski JA. Does reverse triiodothyronine testing have clinical utility? An analysis of practice variation based on order data from a national reference laboratory. Thyroid 2018; 28 (07) 842-848